Clinical studies recruiting near Macomb

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Illinois CancerCare-Macomb · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Illinois CancerCare-Macomb · NRG Oncology · NCT05624996 Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met
Phase 2 · Karmanos Cancer Institute at McLaren Macomb · Barbara Ann Karmanos Cancer Institute · NCT07130903 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT07321652 A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 2/Phase 3 · National Cancer Institute (NCI) · NCT05691478 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT07091617 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Henry Ford Saint John Hospital - Macomb Medical · SWOG Cancer Research Network · NCT06769126 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Illinois CancerCare-Macomb · NRG Oncology · NCT05946213 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · Illinois CancerCare-Macomb · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Illinois CancerCare-Macomb · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT06632327 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT06931340 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Illinois CancerCare-Macomb · National Cancer Institute (NCI) · NCT04269902 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Canadian Cancer Trials Group · NCT06592924 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · Illinois CancerCare-Macomb · NRG Oncology · NCT06748222 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · NRG Oncology · NCT03180268 Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA
NA · Illinois CancerCare-Macomb · Wake Forest University Health Sciences · NCT06904391 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT04242095 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · National Cancer Institute (NCI) · NCT05554393 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Henry Ford Saint John Hospital - Macomb Medical · National Cancer Institute (NCI) · NCT06498635 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Illinois CancerCare-Macomb · Eastern Cooperative Oncology Group · NCT05108298 Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · Illinois CancerCare-Macomb · National Cancer Institute (NCI) · NCT07061964 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Illinois CancerCare-Macomb · ECOG-ACRIN Cancer Research Group · NCT04566328 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Illinois CancerCare-Macomb · NRG Oncology · NCT04852887 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT05677490 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Illinois CancerCare-Macomb · National Cancer Institute (NCI) · NCT06058377 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · Illinois CancerCare-Macomb · SWOG Cancer Research Network · NCT04511013 Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · Illinois CancerCare-Macomb · Alliance for Clinical Trials in Oncology · NCT07215910 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Illinois CancerCare-Macomb · ECOG-ACRIN Cancer Research Group · NCT04239573

Look up another city

Look up another condition